Chimeric Therapeutics Ltd - Asset Resilience Ratio

Latest as of December 2025: 42.22%

Chimeric Therapeutics Ltd (CHM) has an Asset Resilience Ratio of 42.22% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Chimeric Therapeutics Ltd short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

AU$2.50 Million

≈ $1.77 Million USD Cash + Short-term Investments

Total Assets

AU$5.93 Million

≈ $4.20 Million USD All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2021–2022)

This chart shows how Chimeric Therapeutics Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Chimeric Therapeutics Ltd total assets.

Liquid Assets Composition Over Time

This chart breaks down Chimeric Therapeutics Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore long-term investment intensity of Chimeric Therapeutics Ltd to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	AU$2.50 Million	42.22%
Short-term Investments	AU$0.00	0%
Total Liquid Assets	AU$2.50 Million	42.22%

Asset Resilience Insights

Very High Liquidity: Chimeric Therapeutics Ltd maintains exceptional liquid asset reserves at 42.22% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Chimeric Therapeutics Ltd Industry Peers by Asset Resilience Ratio

Compare Chimeric Therapeutics Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Abivax SA PA:ABVX	Biotechnology	2.58%
Shanghai RAAS Blood Products Co Ltd Class A SHE:002252	Biotechnology	2.03%
Neuren Pharmaceuticals Ltd AU:NEU	Biotechnology	90.43%
Lifecome Biochemistry Co Ltd SHE:002868	Biotechnology	4.69%
Pulike Biological Engineering SHG:603566	Biotechnology	17.82%
Rocket Pharmaceuticals Inc NASDAQ:RCKT	Biotechnology	14.00%
NEWRON PHARMACEUT. EO-20 XETRA:NP5	Biotechnology	41.67%
Upstream Bio, Inc. NASDAQ:UPB	Biotechnology	64.70%

Annual Asset Resilience Ratio for Chimeric Therapeutics Ltd (2021–2022)

The table below shows the annual Asset Resilience Ratio data for Chimeric Therapeutics Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2022-06-30	52.70%	AU$18.38 Million ≈ $13.01 Million	AU$34.88 Million ≈ $24.68 Million	-8.69pp
2021-06-30	61.39%	AU$22.41 Million ≈ $15.86 Million	AU$36.50 Million ≈ $25.83 Million	--

pp = percentage points

About Chimeric Therapeutics Ltd

AU:CHM Australia Biotechnology

Market Cap

$220.01K

AU$310.93K AUD

Market Cap Rank

#31316 Global

#1809 in Australia

Share Price

AU$0.01

Change (1 day)

-14.29%

52-Week Range

AU$0.00 - AU$0.21

All Time High

AU$0.39